

# Hepagurd®

L-Ornithine-L-Aspartate  
Granules for Solution

## Description

L-Ornithine-L-Aspartate (LOLA) is a stable salt of two natural nonessential L-amino acids: ornithine and aspartic acid.

In a healthy subject, ammonia produced in the body is excreted by the kidney in the form of urea, the product of the urea cycle, or converted into substances useful for the body. In cases of hepatic disorders, on the other hand, blood ammonia level is known to increase. It is likely that ammonia in high concentrations interferes with the TCA cycle and thus disturbs the completion of carbohydrate and protein metabolism so seriously as to cause inhibition of ATP synthesis and the subsequent liability or aggravation of fatty degeneration of the liver. It is also possible that the impaired brain metabolism due to elevated blood ammonia is liable to cause disturbance of consciousness or to precipitate coma.

L-Ornithine-L-Aspartate (LOLA) has been shown to reduce ammonia and improve psychometric function in patients with hepatic encephalopathy. It is used to lower blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis.

## Indications

- Intensive treatment of severe acute and chronic liver diseases as liver cirrhosis, fatty liver, hepatitis with hyperammonaemia.
- Treatment of associated conditions and sequelae of diseases with impaired hepatic detoxification when there are symptoms and signs of minimal or over hepatic encephalopathy.

## Dosage and Administrations

The content of 1-2 sachets is dissolved in a large amount of fluid (e.g. in a glass of water or juice) and is taken orally 3 times a day during or after meals. The course of treatment is determined individually.

## Side Effects

*Uncommon:* nausea, vomiting, stomachache, flatulence and diarrhea.

*Very rare:* pain in the limbs.

## Contraindications

Hypersensitivity to L-Ornithine-L-Aspartate or any other excipients of these products. Severe renal insufficiency (a serum creatinine level in excess of 3 mg/100 ml can be regarded as the guide value).

## Precautions

L-Ornithine-L-Aspartate granules may be harmful to the teeth (caries) in long-term use.

## Use in Special Populations

*Pregnancy, Lactation and Children*

It is not known whether there are harmful effects from use of the product during pregnancy or while breastfeeding. If treatment is nevertheless thought to be necessary, the benefits and risks should be carefully assessed. It is not known whether L-Ornithine-L-Aspartate penetrates into the breast milk. Therefore, it is recommended to avoid during lactation. The experience of medication use in children is limited, therefore it should not be used in pediatrics.

## Drug Interactions

Not known

## Pharmaceutical Precautions

Keep in a cool & dry place. Protect from light. Keep out of the reach of children.

## Commercial Pack

Hepagurd® Granules for Solution: Box containing 10 sachets of oral granules. Each sachet contains L-Ornithine-L-Aspartate INN 3 g.



Manufactured by

**BEXIMCO PHARMACEUTICALS LTD.**

TONGI, BANGLADESH BL 0925 101116

© Hepagurd is a registered trademark of Beximco Pharmaceuticals Ltd.

